The clinical trial compares the efficacy and safety of Tactile Electrosurgical Ablation (TEA) against traditional Hysteroscopic Electrosurgical Ablation for treating dysfunctional uterine bleeding (DUB) in women aged 40-50. Given that DUB affects up to 30% of women during their reproductive years, there is a significant market opportunity for effective, less invasive treatments. TEA presents as a cost-effective alternative, particularly in resource-limited settings, which may appeal to healthcare systems facing budget constraints. The trial's completion and positive outcomes could position TEA as a viable competitor to existing surgical options, potentially influencing treatment guidelines and expanding market share in gynecological interventions.